| Bioactivity | SOS1-IN-15 (Compound 37) is an orally active SOS1 inhibitor with an IC50 of 5 nM. SOS1-IN-15 is a promising agent candidate for the research of KRAS-driven cancer[1]. | |||||||||
| Invitro | SOS1-IN-15 (Compound 37) (0.1 nM-0.1 mM; 72 h) displays prominent inhibitory activities in Mia-paca-2 cancer cells (IC50 = 178 ± 42 nM)[1].SOS1-IN-15 has a limited inhibition of CYP and hERG[1]. Cell Proliferation Assay[1] Cell Line: | |||||||||
| In Vivo | SOS1-IN-15 (Compound 37) (50 mg/kg; p.o.; daily for 22 days) inhibits tumor volume in mice[1]. Animal Model: | |||||||||
| Name | SOS1-IN-15 | |||||||||
| CAS | 2793404-47-2 | |||||||||
| Formula | C28H27F3N6O2 | |||||||||
| Molar Mass | 536.55 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Zhang S, et al. Design and Structural Optimization of Orally Bioavailable SOS1 Inhibitors for the Treatment of KRAS-Driven Carcinoma. J Med Chem. 2022 Nov 17. |
SOS1-IN-15
CAS: 2793404-47-2 F: C28H27F3N6O2 W: 536.55
SOS1-IN-15 (Compound 37) is an orally active SOS1 inhibitor with an IC50 of 5 nM. SOS1-IN-15 is a promising agent candid
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.